Table 3B.

Intrapatient Recombinants and Their Parental Variants^d

	Plasma parental variant	CVL parental variant	Recombinant
Plasma-derived recombinant
Variant	38P-200-3e	38C-200-25	38P-700-12
Resistance mutations	K103N	A98V, G190S	K103N, M184V, G190S
Genotypic and phenotypic resistance	NNRTI-R	NNRTI-R	NNRTI-R, 3TC-R
RC,† %	87	11	58
CVL fluid-derived recombinant
Variant	38P-200-13	38C-200-1	38C-700-2
Resistance mutations	K103N	A98V, G190S	K103N, M184V
Genotypic and phenotypic resistance	NNRTI-R	NNRTI-Rf	NNRTI, 3TC-R
RC, %	19	9	83

^aDenotes the number and percentage of variants tested for RC that exhibited each single or combination of resistance-associated mutations.

^bRC≥50%, fit; RC 20–49%, intermediate; RC<20%, unfit.

^cThe mean RC of variants bearing both the A98V and G190S mutations was significantly lower than that of the other variants (p=0.007).

^dLikely parental variants were identified by Bayesian analysis.

^eVariants are identified as follows: 38 denotes the patient number; P or C denotes plasma or cervicovaginal lavage as the site of origin of each variant; the numbers that follow denote the month and year the variant was obtained, so that 200 denotes February of 2000; and the final number denotes the particular variant obtained from that compartment on that date.

^fPhenotypic drug resistance could not be ascertained because of low RC.

RC, replicative capacity; CVL, cervicovaginal lavage; NVP, nevirapine; 3TC, lamivudine; R, high-level resistance.